Phase I trial of a 72-h oxymorphone transdermal patch for moderate-to-severe chronic pain.

Trial Profile

Phase I trial of a 72-h oxymorphone transdermal patch for moderate-to-severe chronic pain.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Sep 2013

At a glance

  • Drugs Oxymorphone (Primary)
  • Indications Pain
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 03 Sep 2013 Results will be presented at 2013 PAINWeek according to a Phosphagenics media release.
    • 25 Mar 2013 Primary safety endpoints have been met, according to a Phosphagenics media release.
    • 25 Mar 2013 Status changed to completed, according to a Phosphagenics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top